AngioGenex, Inc. (Ticker: AGGX) announced today that Mr. Michael Aronstein, veteran financier and the President/Chief Investment Officer and Portfolio Manager of Marketfield Asset Management, LLC, has agreed to assume the leadership of the Company’s Board of Directors as non-executive Chairman effective immediately. “I could not be more impressed with the quality of the minds and the science behind AngioGenex. It is a privilege to have a role in the next phase of progress from insight to patient care,” offered the Company’s new Chairman.
“We welcome Mr. Aronstein’s leadership and direction as we progress the development of our novel class of drugs towards human clinical testing,” says the company’s scientific founder and Chief Scientific and Executive Officer, Dr. Robert Benezra. “The addition of his experience, acumen, and contacts to our effort is an important step toward realizing the full potential of our company and its technology.”
AngioGenex, Inc. is a New York-based biopharmaceutical company developing a novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration.
AngioGenex (Ticker: AGGX) is a biopharmaceutical company committed to the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. AngioGenex and its collaborators, including Robert Benezra, Ph.D., and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Id proteins have been shown to play a key role in mediating the pathogenesis of certain cancers and diseases of the eye. AngioGenex’s lead development candidate is AGX-A, a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration (AMD). AngioGenex is headquartered in New York, NY.